JPMorgan Chase & Co. Cuts Cooper Companies (NASDAQ:COO) Price Target to $58.00

Cooper Companies (NASDAQ:COO) had its price objective cut by JPMorgan Chase & Co. from $71.00 to $58.00 in a report published on Thursday morning,Benzinga reports. They currently have a neutral rating on the medical device company’s stock.

A number of other equities research analysts have also recently weighed in on COO. Bank of America reaffirmed a “neutral” rating and issued a $65.00 price objective (down from $80.00) on shares of Cooper Companies in a research note on Thursday. Needham & Company LLC lowered their target price on Cooper Companies from $86.00 to $73.00 and set a “buy” rating for the company in a report on Thursday. Mizuho set a $85.00 target price on Cooper Companies and gave the company an “outperform” rating in a research report on Thursday, June 4th. Citigroup reaffirmed a “neutral” rating and issued a $60.00 target price (down from $80.00) on shares of Cooper Companies in a research report on Thursday. Finally, William Blair lowered shares of Cooper Companies from an “outperform” rating to a “market perform” rating in a research note on Thursday. Five investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $71.47.

Cooper Companies Stock Performance

NASDAQ:COO opened at $53.91 on Thursday. Cooper Companies has a fifty-two week low of $51.01 and a fifty-two week high of $89.83. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.22. The company has a 50 day moving average price of $71.62 and a 200 day moving average price of $69.70. The stock has a market capitalization of $10.25 billion, a P/E ratio of 18.40, a PEG ratio of 1.44 and a beta of 0.82.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The company had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the previous year, the company earned $0.49 earnings per share. The firm’s quarterly revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities research analysts forecast that Cooper Companies will post 4.53 EPS for the current year.

Cooper Companies declared that its board has approved a stock repurchase program on Wednesday, September 9th that permits the company to buyback $3.00 billion in shares. This buyback authorization permits the medical device company to reacquire up to 22.7% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

Institutional Investors Weigh In On Cooper Companies

Hedge funds and other institutional investors have recently modified their holdings of the company. Avalon Trust Co acquired a new position in shares of Cooper Companies during the second quarter worth $25,000. Root Financial Partners LLC raised its stake in Cooper Companies by 104.5% in the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after buying an additional 162 shares in the last quarter. SJS Investment Consulting Inc. raised its stake in Cooper Companies by 107.5% in the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after buying an additional 187 shares in the last quarter. Elevation Wealth Partners LLC lifted its holdings in Cooper Companies by 1,136.4% during the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock worth $29,000 after buying an additional 375 shares during the last quarter. Finally, Continuum Advisory LLC purchased a new stake in Cooper Companies during the 2nd quarter worth about $30,000. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper reported adjusted fiscal Q3 earnings of $1.15 per share, ahead of the approximately $1.11–$1.12 consensus, with earnings up from $0.49 a year earlier. Cost controls and continued fertility-related growth helped offset weakness elsewhere. Cooper Companies Bets on Fertility Growth Despite Weakness in CooperVision
• Positive Sentiment: The board authorized an additional $1 billion of repurchases, bringing the total buyback authorization to $3 billion. The program could support per-share earnings and signal management believes COO shares are undervalued. Cooper Outlines Q4 EPS and Adds to Buyback Authorization
• Neutral Sentiment: Cooper completed a strategic review but chose not to pursue a sale or separate transaction for CooperSurgical. Keeping the business preserves its fertility-growth opportunity, but investors had apparently anticipated a potential deal or value-unlocking action. Cooper Cos. Stock Drops After Soft Outlook and No Deal
• Negative Sentiment: Revenue rose only about 1% to $1.066 billion, missing the roughly $1.10 billion consensus. U.S. channel destocking and inventory reductions pressured CooperVision, raising concerns about near-term demand and sales momentum. COO Q3 Earnings Top Estimates, Revenues Miss on Destocking
• Negative Sentiment: Management reduced fiscal 2026 earnings guidance to $4.51–$4.55 per share and issued fourth-quarter guidance of $1.05–$1.09, below prior expectations. The weaker outlook triggered multiple analyst downgrades and price-target cuts, including from Baird, UBS, JPMorgan and William Blair.
• Negative Sentiment: Law firms have announced securities-fraud investigations connected with the post-earnings decline. These notices are often promotional, but they add to negative investor sentiment and potential legal uncertainty. Securities Fraud Investigation Into Cooper Companies Announced

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.